A detailed history of Avidity Partners Management LP transactions in Century Therapeutics, Inc. stock. As of the latest transaction made, Avidity Partners Management LP holds 1,221,555 shares of IPSC stock, worth $3.11 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares
1,221,555
Previous 1,355,000 9.85%
Holding current value
$3.11 Million
Previous $4.5 Million 13.52%
% of portfolio
0.2%
Previous 0.18%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$3.19 - $5.32 $425,689 - $709,927
-133,445 Reduced 9.85%
1,221,555 $5.11 Million
Q4 2023

Feb 14, 2024

BUY
$1.28 - $3.32 $328,320 - $851,580
256,500 Added 23.35%
1,355,000 $4.5 Million
Q3 2023

Nov 14, 2023

SELL
$2.0 - $3.23 $24,800 - $40,052
-12,400 Reduced 1.12%
1,098,500 $2.2 Million
Q2 2023

Aug 14, 2023

SELL
$2.91 - $3.53 $457,452 - $554,916
-157,200 Reduced 12.4%
1,110,900 $3.51 Million
Q1 2023

May 15, 2023

SELL
$3.4 - $5.11 $120,700 - $181,405
-35,500 Reduced 2.72%
1,268,100 $4.4 Million
Q3 2022

Nov 14, 2022

BUY
$8.57 - $13.1 $3.76 Million - $5.75 Million
438,600 Added 50.71%
1,303,600 $12.9 Million
Q1 2022

May 16, 2022

BUY
$11.62 - $15.92 $156,614 - $214,569
13,478 Added 1.58%
865,000 $10.9 Million
Q4 2021

Feb 14, 2022

BUY
$13.93 - $23.62 $1.56 Million - $2.65 Million
112,253 Added 15.18%
851,522 $13.5 Million
Q3 2021

Nov 15, 2021

SELL
$20.8 - $31.93 $5.5 Million - $8.44 Million
-264,253 Reduced 26.33%
739,269 $18.6 Million
Q2 2021

Aug 16, 2021

BUY
$22.45 - $29.34 $22.5 Million - $29.4 Million
1,003,522 New
1,003,522 $29.4 Million

Others Institutions Holding IPSC

About Century Therapeutics, Inc.


  • Ticker IPSC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,881,800
  • Market Cap $150M
  • Description
  • Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...
More about IPSC
Track This Portfolio

Track Avidity Partners Management LP Portfolio

Follow Avidity Partners Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Avidity Partners Management LP with notifications on news.